Kawachinagano, Japan

Kazuhiko Motoba


Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuhiko Motoba: Innovator in Therapeutic Applications

Introduction

Kazuhiko Motoba is a notable inventor based in Kawachinagano, Japan. He has made significant contributions to the field of therapeutic applications, particularly in the treatment of inflammation and hypertension. His innovative work has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Kazuhiko Motoba holds a patent for "Inhibitors of epoxide hydrolases for the treatment of inflammation." This invention provides compounds that inhibit epoxide hydrolase, which can be utilized in therapeutic applications for treating hypertension. The preferred class of compounds for practicing this invention has a specific structure, where Z can be oxygen or sulfur, W can be carbon, phosphorus, or sulfur, and X and Y can independently be nitrogen, oxygen, or sulfur. This complex structure allows for various applications in medical treatments.

Career Highlights

Kazuhiko Motoba is affiliated with the University of California, where he continues to engage in research and development. His work has been instrumental in advancing the understanding of epoxide hydrolases and their role in inflammation and hypertension.

Collaborations

Kazuhiko has collaborated with esteemed colleagues such as Bruce D Hammock and Jiang Zheng. Their combined expertise has further enhanced the impact of his research and innovations.

Conclusion

Kazuhiko Motoba's contributions to the field of therapeutic applications through his innovative patent demonstrate his commitment to improving health outcomes. His work continues to inspire advancements in medical research and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…